## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Roderico Estanislao, Danilo Lambino, Connie Lim,

Maki Sugimoto

Serial No. :

Art Unit:

Filed

Examiner:

For

PRODUCT FOR ADMINISTRATION OF ACTIVE AGENTS TO

DIFFERENT AREAS OF THE SKIN

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

October 7, 2003
(Date of Deposit)

William E. McGowan
(Name of applicant, assignee, or Registered Representative)

(Signature)

October 7, 2003

(Date of Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information

 $\boxtimes$ 

accompanied by one of:

Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required. In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with | the first or second After Final Submission, therefore: Statement in Accordance with §1.97(e) П (attached); or Please charge Deposit Account No. 10-0750/ the fee of \$180.00 as set forth / in §1.17(p). In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final

Action under §1.113 or a Notice of Allowance under §1.311, or

an action that otherwise closes prosecution and that it is

	Statement in Accordance with §1.97(e)
	(attached); or
	Please charge Deposit Account No. 10-
	0750/ / the fee of \$180.00 as set forth
	in §1.17(p).
☐ In	accordance with §1.97(d), this Information
Disclosure St	atement is being filed after the mailing date of
either a Fina	l Action under §1.113 or a Notice of Allowance
under §1.311	but before the payment of the Issue Fee.
Applicant(s)	hereby petition(s) for consideration of this
Information D	isclosure Statement. Included are: Statement in
Accordance wi	th §1.97(e) as set forth below and the fee of
\$180.00 as se	t forth in §1.17(p).
	pies of each of the references listed on the
attached Form	PTO-1449 are enclosed herewith.
⊠ Cop	oies of references listed on the attached Form PTO
1449 are encl	osed herewith EXCEPT THAT:
	In view of the voluminous nature of references
	[list as appropriate], and the likelihood that
	these references are available to the Examiner,
	copies are not enclosed herewith.
	If any of the foregoing publications are not
	available to the Examiner, Applicant will
	endeavor to supply copies at the Examiner's
	request.
	oies of only foreign patent documents and non-
patent litera	ture are enclosed in accordance with 37 CFR 1.98
(a)(2). (The	U.S. patents and each U.S. patent application

publication listed on the attached Form PTO-1449 are not

enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i). There are no listed references which are not in the English language.  $\boxtimes$ The relevance of those listed references which are not in the English language is as follows: Japanese patent abstracts, Japanese patents and Japanese packaging are with English translations attached Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D. Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D. Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/J&J-5081/WEM. This form is submitted in triplicate. Respectfully submitted, iam E. McGowan Req. No. 39,301 Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2197
DATED: October 7, 2003

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 3

a collection of information unless it displays	a valid UMB control number.
Application Number	
Filing Date	
First Named Inventor	Roderico Estanislao
Group Art Unit	
Examiner Name	
Attorney Docket Number	J&J-5081

	SHEET 1013					
				U.S. PATENT DOCUMENTS		
		U.S. Patent Do		Name of Patentee or Applicant	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant passages
Examiner Initials	Cite No.1	Number	Kind Code <sup>2</sup> (if known)	of Cited Document	mm-dd-yyyy	or relevant figures appear
	ļ	3,896,807		Buchalter	07/29/1975	
		4,591,501		Cioca	05/27/1986	
		5,026,552		Gueret et al.	06/25/1991	
	<u> </u>	5,227,242		Walter et al.	07/13/1993	
	<del>                                     </del>	5,466,465		Royds et al.	11/14/1995	
	<del> </del>	6,120,784		Snyder, Jr.	09/19/2000	
	+-	6,159,493		Chen et al.	12/12/2000	
	<del>                                     </del>	6,316,021	B1	Gueret	11/13/2001	
	+	6,365,135	B1	Philippe et al.	04/02/2002	
<b> </b>	+-	6,410,017		Weisgerber et al.	06/25/2002	
ļ	<del> </del> -	6,503,232	B1	Kawai et al.	07/07/2003	
<u> </u>	+-	6,521,241	B1	Minerath, III et al.	02/18/2003	
<u> </u>				EIGN PATENT DOCUMENTS		

#### FOREIGN PATENT DOCUMENTS Pages, Columns, Lines, Date of Publication Foreign Patent Document where relevant of Cited Document Name of Patentee or passages or relevant Τ<sup>6</sup> mm-dd-yyyy Examiner Cite Applicant of Cited Document figures appear KindCode<sup>5</sup> Initials Office<sup>3</sup> Number⁴ No.1 09/12/1997 Kao Corporation wo A1 **PCT** 97/32567 01/11/2001 The Procter & Gamble Company wo **A1** PCT 01/02479 01/11/2001 The Procter & Gamble Company wo Α1 PCT 01/02478 01/11/2001 The Procter & Gamble Company A2 wo 01/02028 01/11/2001 The Procter & Gamble Company PCT 01/01951 01/11/2001 The Procter & Gamble Company A2 wo 01/01933 10/26/2000 Acutek International PCT WP 00/62763

	Date	
Examiner	Considered	
Signature	ADED 600. Draw line through citation if	not in conformance

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 3

Application Number	
Filing Date	
First Named Inventor	Roderico Estanislao
Group Art Unit	
Examiner Name	
Attorney Docket Number	J&J-5081

**U.S. PATENT DOCUMENTS** 

		U.S. Patent Docur	nent		Date of Publication	Pages, Columns, Lines,
Examiner Initials	Cite No. <sup>1</sup>	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document mm-dd-yyyy	where relevant passages or relevant figures appear
		6,551,607	B1	Minerath, III et al.	04/22/2003	
		2003/0027738	A1	Delambre et al.	02/06/2003	
		2003/0044366	A1	Dole et al.	03/06/2003	

### **FOREIGN PATENT DOCUMENTS**

		Foreign	Patent Document		Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials	Cite No. <sup>1</sup>	Office <sup>3</sup>	Number <sup>4</sup> Kind	lCode <sup>5</sup>	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T⁵
		PCT	WO 02/062132	A2	The Procter & Gamble Company	08/15/2002		
		JP	11322538		Shiseido Co. Ltd.	11/24/1999		Т
		JP	11130624		Kao Corporation	05/18/1999		Т
		JP	2000 256162		Pola Chemical Ind Inc.	09/19/2000		Т
		JP	1149635		Nitto Denko Corporation	02/23/1999		т
		JP	11228340		Nitto Denko Corporation	08/24/1999		Т
		JP	2000136112		Ohashi Yoshitaka	05/16/2000		т
		JР	1081612		Asahi Chemical Industry Co. Ltd.	03/31/1998		т

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substitute for form 1449A/PT

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 3 of 3

a concessit of attornia and atties a ampays	a valid Cities College Hallistel.
Application Number	
Filing Date	
First Named Inventor	R derico Estanislao
Group Art Unit	
Examiner Name	
Attorney Dock t Number	J&J-5081
-	

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner's	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>			
		TSC TU-Zone Mask Nourishing Type packaging, publicly available prior to October 7, 2003.	T			
		TSC TU-Zone Mask Fresh Type packaging, publicly available prior to October 7, 2003.	T			
		Neutrogena® Fine Fairness Mask Hydrating Vitamin C Formula, packaging, publicly available prior to October 7, 2003.				
		Neutrogena® Hydrating Facial™ Cloth Mask, Relaxing at-Home Facial packaging, publicly available prior to October 7, 2003				
	l					
ļ	ļ		<b> </b>			
	<del> </del>					
	<b>-</b>					

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.